VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 13, 2007) - ALDA Pharmaceuticals Corp. ("ALDA") (TSX VENTURE:APH) announces that Brand Institute, Inc. has been selected to assist with marketing efforts in the US and internationally. Dr. Terrance Owen, President & CEO comments, "As we make progress with the development of retail and therapeutic applications of the T36(R) technology, a strong US and international presence is important. ALDA needs to align its marketing efforts with its anticipated European and FDA product registrations and the proposed listing of its shares in the US. Due to their strong US and international presence, we have selected Brand Institute, Inc. to work with us so that ALDA can achieve success in its targeted markets."

About Brand Institute, Inc.

Brand Institute, Inc. offers pharmaceutical naming, packaging and labeling, trademarking and market research services, as well as global regulatory insight provided by former key officials from the FDA and Health Canada. With offices in the US, Europe and Asia, Brand Institute Inc. will provide strategic and regulatory assistance that will be very important to ALDA as it establishes its presence in markets outside of Canada.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.